Patents by Inventor Michihiro HOSOJIMA

Michihiro HOSOJIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR DETERMINING PRESENCE/ABSENCE OF NOROVIRUS INFECTION RISK
    Publication number: 20230366890
    Abstract: The present invention provides a method of assisting a determination of whether a subject is susceptible to infection by norovirus or whether a subject is susceptible to post-infection worsening, wherein this method contains a step of measuring the concentration of IgG antibody that is present in a sample originating from within the oral cavity of the subject.
    Type: Application
    Filed: October 7, 2021
    Publication date: November 16, 2023
    Applicants: Niigata University, Denka Company Limited
    Inventors: Akihiko SAITO, Michihiro HOSOJIMA, Hideyuki KABASAWA, Nobumasa AOKI, Kei NAGANO, Sakari SEKINE, Keisuke MUNEKATA
  • Megalin antagonist
    Patent number: 10420741
    Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: September 24, 2019
    Assignees: EA Pharma Co., Ltd., Niigata University
    Inventors: Akihiko Saito, Nobumasa Aoki, Yoshihisa Hori, Shoji Kuwahara, Michihiro Hosojima, Hiroshi Iwata, Saori Matsuda
  • MEGALIN ANTAGONIST
    Publication number: 20160324813
    Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof
    Type: Application
    Filed: July 21, 2016
    Publication date: November 10, 2016
    Applicants: EA Pharma Co., Ltd., Niigata University
    Inventors: Akihiko SAITO, Nobumasa AOKI, Yoshihisa HORI, Shoji KUWAHARA, Michihiro HOSOJIMA, Hiroshi IWATA, Saori MATSUDA